Short answer
10x Genomics, Inc. (TXG) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $151M (down 12.6% year over year) with net income of −$18M.
Q2 2026 key financials · XBRL
- Revenue
- $151M
- −12.6% YoY · +0.1% QoQ
- Net income
- −$18M
- −151.9% YoY · −33.1% QoQ
- Operating margin
- -12.9%
- Gross margin
- 74.5%
- EPS (diluted)
- −$0.14
- −150.0% YoY · −40.0% QoQ
Source: XBRL data from the 10x Genomics, Inc. (TXG) Q2 2026 10-Q on SEC EDGAR. USD.
10x Genomics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $151.0M, down 13% YoY from $172.9M, driven by license and royalty revenue falling 93% to $1.9M
- Gross margin 74% vs 72% YoY; gross profit $112.5M vs $125.1M
- Best segment Spatial consumables $42.3M, up 16%; worst Spatial instruments $4.6M, down 48%
- Cash and securities $552.0M, up $28.6M; operating cash flow $43.1M vs $52.1M YoY
- Outlook: 2026 revenue expected to moderately increase excluding litigation revenue; operating expenses expected to modestly decrease
Risk Factors
- No material changes to previously disclosed 10-K risk factors
- No newly added quarterly risk factor or identified trigger
- No new regulatory, legal, or compliance risk disclosed
- No updated operational, competitive, or market risk disclosed
- No updated liquidity, debt, currency, or concentration risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other 10x Genomics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.